Valuation: Aquestive Therapeutics, Inc.

Market Cap 542M 465M 434M 398M 749M 51.83B 762M 5.12B 2.01B 25.99B 2.04B 1.99B 85.94B P/E 2026 *
-8.31x
P/E 2027 * -8.66x
Enterprise Value 464M 398M 372M 341M 642M 44.37B 652M 4.39B 1.72B 22.25B 1.74B 1.71B 73.58B EV / Sales 2026 *
9.3x
EV / Sales 2027 * 7.9x
Free-Float
96.95%
Yield 2026 *
-
Yield 2027 * -
1 day+7.29%
1 week+10.05%
Current month+25.98%
1 month+18.00%
3 months+13.81%
6 months+17.55%
Current year-27.94%
1 week 4.02
Extreme 4.015
4.74
1 month 3.56
Extreme 3.56
4.74
Current year 2.93
Extreme 2.93
6.59
1 year 2.93
Extreme 2.93
7.55
3 years 1.25
Extreme 1.2514
7.55
5 years 0.62
Extreme 0.618
7.55
10 years 0.62
Extreme 0.618
20.7
Manager TitleAgeSince
Chief Executive Officer 50 17/05/2022
Director of Finance/CFO 67 31/12/2020
Compliance Officer - 02/04/2026
Director TitleAgeSince
Chairman 72 01/04/2024
Director/Board Member 60 01/01/2004
Director/Board Member 50 17/05/2022
Date Insider Type Main position Quantity % Market Cap.
14/8/26 Tax

Executive/Senior Manager

-2,714 0.0022%
16/7/26 Sell

Chief Executive Officer

-20,369 0.0162%
9/3/26 Free

General Counsel

200,311 0.1642%
Change 5-day change 1-year change 3-year change Capi.($)
+7.29%+10.05%+20.91%+162.99% 542M
+4.80%+5.40%+82.89%+133.82% 1,093B
+1.09%+4.96%+54.00%+63.62% 653B
+3.04%+7.01%+29.10%+77.28% 458B
+1.80%+0.52%+41.20%+44.48% 355B
+1.24%+2.35%+25.99%+41.24% 294B
+2.07%+2.97%+2.27%+12.89% 248B
+4.10%+6.30%+49.68%+69.69% 230B
+1.05%-0.02%-13.96%-52.51% 203B
+3.59%+9.35%+25.94%+95.65% 178B
Average +2.99%+0.88%+31.80%+64.92% 371.1B
Weighted average by Cap. +2.85%+1.45%+47.21%+74.56%

Financials

2026 *2027 *
Net sales 49.92M 42.82M 39.99M 36.69M 68.99M 4.77B 70.13M 472M 185M 2.39B 187M 183M 7.91B 68.62M 58.86M 54.96M 50.43M 94.83M 6.56B 96.39M 649M 254M 3.29B 258M 252M 10.88B
Net income -64.73M -55.53M -51.85M -47.57M -89.46M -6.19B -90.93M -612M -240M -3.1B -243M -238M -10.26B -62.34M -53.48M -49.93M -45.81M -86.15M -5.96B -87.57M -589M -231M -2.99B -234M -229M -9.88B
Net Debt -78M -66.91M -62.48M -57.32M -108M -7.46B -110M -737M -289M -3.74B -293M -287M -12.36B -
Logo Aquestive Therapeutics, Inc.
Aquestive Therapeutics, Inc. is a pharmaceutical company. The Company is engaged in developing orally administered and topical gel products to deliver complex molecules, providing novel alternatives to invasive and inconvenient standard of care therapies. It has four commercialized products marketed by the Company’s licensees in the United States and around the world and is the manufacturer of these licensed products. The Company also collaborates with pharmaceutical companies to bring new molecules to market using proprietary technologies, including PharmFilm, and has proven drug development and commercialization capabilities. The Company is advancing a late-stage proprietary product candidate for the treatment of severe allergic reactions, including anaphylaxis, and an early-stage epinephrine prodrug topical gel product candidate for various possible dermatology conditions. Its portfolio includes Anaphylm, AQST-108, Libervant, Suboxone, and Emylif.
Employees
147
Date Price Change Volume
20/08/26 US$4.655 +7.75% 6,854,554
18/08/26 US$4.320 +0.70% 5,455,979
17/08/26 US$4.290 +0.94% 3,338,666
14/08/26 US$4.250 0.00% 4,350,128
13/08/26 US$4.250 +0.47% 3,745,394
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
4.320USD
Average target price
9.333USD
Spread / Average Target
+116.05%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. AQST Stock